[Current situation and issues in preoperative autologous blood donation in Japan].
Preoperative autologous blood donation (PABD) with no risk of blood-borne infection transmission has been considered the supreme blood transfusion therapy, and it has been reported to decrease incidence of postoperative deep-vein thrombosis. However, the need for PABD has decreased in the USA, because 1) risk of blood-borne infection transmission through allogeneic blood transfusion (ABT) has decreased after introduction of nucleic acid amplification test (NAT), and 2) blood collection-induced anemia has been found in many cases due to inapplicability of erythropoietin (rEPO). ABT risks are decreasing in Japan as in the USA, however, ABT has several issues proper to Japan, such as, outpacing of blood demand over supply in the near future and increase of HIV positive donors. Also, as rEPO can be used in Japan, PABD-induced anemia risks are low. Accordingly, necessity of PABD should increase in Japan. However, as those who usually perform PABD in Japan are surgeons, big issues arise such as bacterial contamination during blood collection and ABO incompatibility during transfusion. Underutilization of PABD in gastrointestinal cancer surgery should also be addressed. Appropriate technique and methodology must be established to increase the safety of PABD and to spread PABD in cancer surgery.
Wakimoto
Nobuhiro
N
Department of Orthpaedic Surgery, Teikyo University School of Medicine, Tokyo, Japan.
D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D001782:Blood Donors; D001787:Blood Group Incompatibility / Q000517:prevention & control; D001804:Blood Transfusion, Autologous / Q000009:adverse effects / Q000191:economics / Q000379:methods / Q000706:statistics & numerical data; D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000627:therapeutic use; D015658:HIV Infections / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D007564:Japan; D019300:Medical Errors / Q000517:prevention & control; D011183:Postoperative Complications / Q000517:prevention & control; D011300:Preoperative Care; D011994:Recombinant Proteins; D012449:Safety; D020246:Venous Thrombosis / Q000517:prevention & control
D011994:Recombinant Proteins; D004921:Erythropoietin